Biotech | April 03, 2022
USFDA approves Yescarta as first CAR T-cell therapy for Lymphoma
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
One of the most advanced cancer care centres in the state of Odisha, it is equipped with the latest technology and a highly experienced multi-disciplinary team of oncologists
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
India accounts for more than half (almost 60%) of new leprosy cases worldwide, despite being declared ‘leprosy-free’ in 2005.
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
Subscribe To Our Newsletter & Stay Updated
